Although several studies have shown that chronic administration of CB2 agonists ameliorates cognitive impairment and gliosis in AD models with App gene overexpression or Aβ injection [13, 15, 17–19], the detailed mechanisms of action of CB2 agonists as therapeutic agents in AD remain unclear. The gene discussed is CNR2; the disease is Cognitive impairment.